Gun Ho Jang
YOU?
Author Swipe
View article: Whole genome and transcriptome profiling in advanced pancreatic cancer patients on the COMPASS trial
Whole genome and transcriptome profiling in advanced pancreatic cancer patients on the COMPASS trial Open
Integrated whole genome and transcriptome sequencing can unveil distinct molecular subgroups in pancreatic cancer (PDAC). The COMPASS trial (NCT02750657) enrolled 268 patients with advanced PDAC; patients were given either modified (m) FOL…
View article: HMGA2 and protein leucine methylation drive pancreatic cancer lineage plasticity
HMGA2 and protein leucine methylation drive pancreatic cancer lineage plasticity Open
Basal pancreatic ductal adenocarcinoma (PDAC) has the worst overall survival and is the only subtype that serves as an independent poor prognostic factor. We identify elevated levels of LIN28B and its downstream target, HMGA2, in basal PDA…
View article: Supplementary Figures from MICAL2 Promotes Pancreatic Cancer Growth and Metastasis
Supplementary Figures from MICAL2 Promotes Pancreatic Cancer Growth and Metastasis Open
Supplementary Figures S1-S8
View article: Supplementary Tables S1-S6 from MICAL2 Promotes Pancreatic Cancer Growth and Metastasis
Supplementary Tables S1-S6 from MICAL2 Promotes Pancreatic Cancer Growth and Metastasis Open
supplementary tables S1-S6
View article: Data from MICAL2 Promotes Pancreatic Cancer Growth and Metastasis
Data from MICAL2 Promotes Pancreatic Cancer Growth and Metastasis Open
Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest solid cancers; thus, identifying more effective therapies is a major unmet need. In this study, we characterized the super-enhancer (SE) landscape of human PDAC to identi…
View article: Supplementary Legends from MICAL2 Promotes Pancreatic Cancer Growth and Metastasis
Supplementary Legends from MICAL2 Promotes Pancreatic Cancer Growth and Metastasis Open
Supplementary Figures and Tables legends.
View article: Supplementary Table S7 from MICAL2 Promotes Pancreatic Cancer Growth and Metastasis
Supplementary Table S7 from MICAL2 Promotes Pancreatic Cancer Growth and Metastasis Open
Supplementary Table S7
View article: Supplementary Table S8 from MICAL2 Promotes Pancreatic Cancer Growth and Metastasis
Supplementary Table S8 from MICAL2 Promotes Pancreatic Cancer Growth and Metastasis Open
Supplementary Table S8
View article: Supplementary Figure S5 from HMGA2 Expression Predicts Subtype, Survival, and Treatment Outcome in Pancreatic Ductal Adenocarcinoma
Supplementary Figure S5 from HMGA2 Expression Predicts Subtype, Survival, and Treatment Outcome in Pancreatic Ductal Adenocarcinoma Open
Supplementary Figure S5. Representative CD8+ and FAP+ scoring. CD8 (top) and FAP (bottom) were scored on a scale of 0 (least staining) to 3 (most staining) following the representative scale.
View article: Supplementary Figure S4 from HMGA2 Expression Predicts Subtype, Survival, and Treatment Outcome in Pancreatic Ductal Adenocarcinoma
Supplementary Figure S4 from HMGA2 Expression Predicts Subtype, Survival, and Treatment Outcome in Pancreatic Ductal Adenocarcinoma Open
Supplementary Figure S4. CK5 and CK17 do not predict treatment response or time to recurrence. A) Combining CK5 and GATA6 IHC does not predict overall survival. B) CK17 high, GATA6 low tumors display improved survival compared to CK17 low,…
View article: Supplementary Figure S2 from HMGA2 Expression Predicts Subtype, Survival, and Treatment Outcome in Pancreatic Ductal Adenocarcinoma
Supplementary Figure S2 from HMGA2 Expression Predicts Subtype, Survival, and Treatment Outcome in Pancreatic Ductal Adenocarcinoma Open
Supplementary Figure S2. Demographic data for analyzed cohort. A) Age distribution for TMA and Ochsner cohorts. B) Race distribution for TMA and Ochsner cohorts. C) Proportions of disease by stage (left) and resulting survival (right) pred…
View article: Supplementary Table S4 from HMGA2 Expression Predicts Subtype, Survival, and Treatment Outcome in Pancreatic Ductal Adenocarcinoma
Supplementary Table S4 from HMGA2 Expression Predicts Subtype, Survival, and Treatment Outcome in Pancreatic Ductal Adenocarcinoma Open
Supplementary Table S4. Chemotherapy Regimens.
View article: Supplementary Figure S1 from HMGA2 Expression Predicts Subtype, Survival, and Treatment Outcome in Pancreatic Ductal Adenocarcinoma
Supplementary Figure S1 from HMGA2 Expression Predicts Subtype, Survival, and Treatment Outcome in Pancreatic Ductal Adenocarcinoma Open
Supplementary Figure S1. Example images of IHC of FFPE samples. A) HMGA2 positive glands. B) GATA6 positive glands. Scale bars = 50 μm.
View article: Supplementary Table S2 from HMGA2 Expression Predicts Subtype, Survival, and Treatment Outcome in Pancreatic Ductal Adenocarcinoma
Supplementary Table S2 from HMGA2 Expression Predicts Subtype, Survival, and Treatment Outcome in Pancreatic Ductal Adenocarcinoma Open
Supplementary Table S2. mIHC Panel.
View article: Supplementary Table S5 from HMGA2 Expression Predicts Subtype, Survival, and Treatment Outcome in Pancreatic Ductal Adenocarcinoma
Supplementary Table S5 from HMGA2 Expression Predicts Subtype, Survival, and Treatment Outcome in Pancreatic Ductal Adenocarcinoma Open
Supplementary Table S5. Representativeness of Study Participants.
View article: Supplementary Figure S3 from HMGA2 Expression Predicts Subtype, Survival, and Treatment Outcome in Pancreatic Ductal Adenocarcinoma
Supplementary Figure S3 from HMGA2 Expression Predicts Subtype, Survival, and Treatment Outcome in Pancreatic Ductal Adenocarcinoma Open
Supplementary Figure S3. Consort Diagram and Mixed Populations. A) Consort diagram of analyzed samples. For survival analyses, all patients with intact cores (n = 491) were assessed. For treatment response analyses, patients were further s…
View article: Supplementary Figure S4 from HMGA2 Expression Predicts Subtype, Survival, and Treatment Outcome in Pancreatic Ductal Adenocarcinoma
Supplementary Figure S4 from HMGA2 Expression Predicts Subtype, Survival, and Treatment Outcome in Pancreatic Ductal Adenocarcinoma Open
Supplementary Figure S4. CK5 and CK17 do not predict treatment response or time to recurrence. A) Combining CK5 and GATA6 IHC does not predict overall survival. B) CK17 high, GATA6 low tumors display improved survival compared to CK17 low,…
View article: Supplementary Figure S2 from HMGA2 Expression Predicts Subtype, Survival, and Treatment Outcome in Pancreatic Ductal Adenocarcinoma
Supplementary Figure S2 from HMGA2 Expression Predicts Subtype, Survival, and Treatment Outcome in Pancreatic Ductal Adenocarcinoma Open
Supplementary Figure S2. Demographic data for analyzed cohort. A) Age distribution for TMA and Ochsner cohorts. B) Race distribution for TMA and Ochsner cohorts. C) Proportions of disease by stage (left) and resulting survival (right) pred…
View article: Supplementary Figure S6 from HMGA2 Expression Predicts Subtype, Survival, and Treatment Outcome in Pancreatic Ductal Adenocarcinoma
Supplementary Figure S6 from HMGA2 Expression Predicts Subtype, Survival, and Treatment Outcome in Pancreatic Ductal Adenocarcinoma Open
Supplementary Figure S6. GATA6 expression predicts chemotherapy response to GnP but not mFFX. A) GATA6low metastatic tumors have significantly worse overall survival when treated with combination GnP first-line chemotherapy. B) GATA6 statu…
View article: Supplementary Table S3 from HMGA2 Expression Predicts Subtype, Survival, and Treatment Outcome in Pancreatic Ductal Adenocarcinoma
Supplementary Table S3 from HMGA2 Expression Predicts Subtype, Survival, and Treatment Outcome in Pancreatic Ductal Adenocarcinoma Open
Supplementary Table S3. HMGA2 vs GATA6 Differential Genes.
View article: Supplementary Table S5 from HMGA2 Expression Predicts Subtype, Survival, and Treatment Outcome in Pancreatic Ductal Adenocarcinoma
Supplementary Table S5 from HMGA2 Expression Predicts Subtype, Survival, and Treatment Outcome in Pancreatic Ductal Adenocarcinoma Open
Supplementary Table S5. Representativeness of Study Participants.
View article: Supplementary Table S3 from HMGA2 Expression Predicts Subtype, Survival, and Treatment Outcome in Pancreatic Ductal Adenocarcinoma
Supplementary Table S3 from HMGA2 Expression Predicts Subtype, Survival, and Treatment Outcome in Pancreatic Ductal Adenocarcinoma Open
Supplementary Table S3. HMGA2 vs GATA6 Differential Genes.
View article: Supplementary Table S1 from HMGA2 Expression Predicts Subtype, Survival, and Treatment Outcome in Pancreatic Ductal Adenocarcinoma
Supplementary Table S1 from HMGA2 Expression Predicts Subtype, Survival, and Treatment Outcome in Pancreatic Ductal Adenocarcinoma Open
Supplementary Table S1. Cohort Demographics.
View article: Supplementary Figure S1 from HMGA2 Expression Predicts Subtype, Survival, and Treatment Outcome in Pancreatic Ductal Adenocarcinoma
Supplementary Figure S1 from HMGA2 Expression Predicts Subtype, Survival, and Treatment Outcome in Pancreatic Ductal Adenocarcinoma Open
Supplementary Figure S1. Example images of IHC of FFPE samples. A) HMGA2 positive glands. B) GATA6 positive glands. Scale bars = 50 μm.
View article: Supplementary Table S4 from HMGA2 Expression Predicts Subtype, Survival, and Treatment Outcome in Pancreatic Ductal Adenocarcinoma
Supplementary Table S4 from HMGA2 Expression Predicts Subtype, Survival, and Treatment Outcome in Pancreatic Ductal Adenocarcinoma Open
Supplementary Table S4. Chemotherapy Regimens.
View article: Supplementary Table S2 from HMGA2 Expression Predicts Subtype, Survival, and Treatment Outcome in Pancreatic Ductal Adenocarcinoma
Supplementary Table S2 from HMGA2 Expression Predicts Subtype, Survival, and Treatment Outcome in Pancreatic Ductal Adenocarcinoma Open
Supplementary Table S2. mIHC Panel.
View article: Supplementary Table S1 from HMGA2 Expression Predicts Subtype, Survival, and Treatment Outcome in Pancreatic Ductal Adenocarcinoma
Supplementary Table S1 from HMGA2 Expression Predicts Subtype, Survival, and Treatment Outcome in Pancreatic Ductal Adenocarcinoma Open
Supplementary Table S1. Cohort Demographics.
View article: Supplementary Figure S3 from HMGA2 Expression Predicts Subtype, Survival, and Treatment Outcome in Pancreatic Ductal Adenocarcinoma
Supplementary Figure S3 from HMGA2 Expression Predicts Subtype, Survival, and Treatment Outcome in Pancreatic Ductal Adenocarcinoma Open
Supplementary Figure S3. Consort Diagram and Mixed Populations. A) Consort diagram of analyzed samples. For survival analyses, all patients with intact cores (n = 491) were assessed. For treatment response analyses, patients were further s…